Drugs targeting mitochondrial functions to control tumor cell growth

Biochemical Pharmacology

Volumn 70, Issue 1, 2005, Pages 1-12

  Dias, Nathalie ^a   Bailly, Christian ^a,b  

^a CENTRE OSCAR LAMBRET   (France)

^b INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

Apoptosis; Cancer chemotherapy; Mitochondria; Permeability transition pore; Respiratory chain

Indexed keywords

1 (2 HYDROXY 5 TRIFLUOROMETHYLPHENYL) 5 TRIFLUOROMETHYL 2(3H) BENZIMIDAZOLONE; 1 (5 CHLORO 2 HYDROXYPHENYL) 5 TRIFLUOROMETHYL 2 BENZIMIDAZOLONE; 1 ETHYL 2 [[3 ETHYL 5 (3 METHYLBENZOTHIAZOLIN 2 YLIDENE) 4 OXOTHIAZOLIDIN 2 YLIDENE]METHYL]PYRIDINIUM CHLORIDE; 17ALPHA ESTRADIOL; 2 AMINO 6 BROMO 4 (1 CYANO 2 ETHOXY 2 OXOETHYL) 4H CHROMENE 3 CARBOXYLIC ACID ETHYL ESTER; 4' CHLORODIAZEPAM; 6 [3 (1 ADAMANTYL) 4 HYDROXYPHENYL] 2 NAPHTHOIC ACID; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; APOPTOLIDIN; AZELAIC ACID; BENZOTHIAZINE DERIVATIVE; BETULIC ACID; BONGKREKIC ACID; CIPROFLOXACIN; CITRININ; CROMAKALIM; CYCLOSPORIN A; DEQUALINIUM; DIAZOXIDE; DITERCALINIUM; DNA; DNA TOPOISOMERASE INHIBITOR; EMD 57970; EMD 60480; ETHIDIUM; ETOPOSIDE; GOSSYPOL; IMEXON; INTERCALATING AGENT; LEVOSIMENDAN; LONIDAMINE; MALONIC ACID; MINOXIDIL; MITOGUAZONE; MOFAROTENE; MP 6; MQ 18; MYXOTHIAZOL; N METHYL 2 DODECYL 3 METHYLQUINOLINIUM; N METHYL 4 [2 METHYL 3 (4 TERT BUTYLPHENYL)]PROPYLPYRIDINIUM; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; NALIDIXIC ACID; NSC 365400; OLIGOMYCIN; PENTAMIDINE; PICEATANNOL; POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT; PROTEIN BCL 2; PYRIDINIUM DERIVATIVE; QUINOLONE DERIVATIVE; RESVERATROL; ROLLINIASTATIN 1; ROTENONE; TACRINE; TENIPOSIDE; THIAZOLIDINE DERIVATIVE; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

APOPTOSIS; BIOGENESIS; CALCIUM TRANSPORT; CANCER CONTROL; CELL PROLIFERATION; DEGENERATIVE DISEASE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG TARGETING; ENERGY METABOLISM; HUMAN; MITOCHONDRION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RESPIRATORY CHAIN; REVIEW; TUMOR GROWTH; ULTRASTRUCTURE;

EID: 20444429105     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2005.03.021     Document Type: Note

References (75)

1. A. Rempel, S.P. Mathupala, C.A. Griffin, A.L. Hawkins, and P.L. Pedersen Glucose catabolism in cancer cells: amplification of the gene encoding type II hexokinase Cancer Res 56 1996 2468 2471
2. P. Costantini, E. Jacotot, D. Decaudin, and G. Kroemer Mitochondrion as a novel target of anticancer chemotherapy J Natl Cancer Inst 92 2000 1042 1053
3. A. Szewczyk, and L. Wojtczak Mitochondria as a pharmacological target Pharmacol Rev 54 2002 101 127
4. M.S. Fliss, H. Usadel, O.L. Caballero, L. Wu, M.R. Buta, and S.M. Eleff Facile detection of mitochondrial DNA mutations in tumors and bodily fluids Science 287 2000 2017 2019
5. K. Polyak, Y. Li, H. Zhu, C. Lengauer, J.K. Willson, and S.D. Markowitz Somatic mutations of the mitochondrial genome in human colorectal tumours Nat Genet 20 1998 291 293
6. J. Wang, J.P. Silva, C.M. Gustafsson, P. Rustin, and N.G. Larsson Increased in vivo apoptosis in cells lacking mitochondrial DNA gene expression Proc Natl Acad Sci 98 2001 4038 4043
7. K.K. Singh, J. Russell, B. Sigala, Y. Zhang, J. Williams, and K.F. Keshav Mitochondrial DNA determines the cellular response to cancer therapeutic agents Oncogene 18 1999 6641 6646
8. G. Moyle Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity Clin Ther 22 2000 911 936
9. C.H. Tsai, S.L. Doong, D.G. Johns, J.S. Driscoll, and Y.C. Cheng Effect of anti-HIV 2′-beta-fluoro-2′,3′-dideoxynucleoside analogs on the cellular content of mitochondrial DNA and on lactate production Biochem Pharmacol 48 1994 1477 1481
10. Y. Mo, Y. Gan, S. Song, J. Johnston, X. Xiao, and M.G. Wientjes Simultaneous targeting of telomeres and telomerase as a cancer therapeutic approach Cancer Res 63 2003 579 585
11. M. Barile, D. Valenti, S. Passarella, and E. Quagliariello 3′-Azido-3′-deoxythmidine uptake into isolated rat liver mitochondria and impairment of ADP/ATP translocator Biochem Pharmacol 53 1997 913 920
12. A. Wiseman, and G. Attardi Reversible tenfold reduction in mitochondria DNA content of human cells treated with ethidium bromide Mol Gen Genet 167 1978 51 63
13. M. Okamaoto, T. Ohsato, K. Nakada, K. Isobe, J.N. Spelbrink, and J. Hayashi Ditercalinium chloride, a pro-anticancer drug, intimately associates with mammalian mitochondrial DNA and inhibits its replication Curr Genet 43 2003 364 370
14. R. Fellous, D. Coulaud, I. el Abed, B.P. Roques, J.B. Le Pecq, and E. Delain Cytoplasmic accumulation of ditercalinium in rat hepatocytes and induction of mitochondrial damage Cancer Res 48 1988 6542 6549
15. J.W. Lawrence, S. Darkin-Rattray, F. Xie, A.H. Neims, and T.C. Rowe 4-Quinolones cause a selective loss of mitochondrial DNA from mouse L1210 leukemia cells J Cell Biochem 51 1993 165 174
16. J.H. Lin, and F.J. Castora DNA topoisomerase II from mammalian mitochondria is inhibited by the antitumor drugs, m-AMSA and VM-26 Biochem Biophys Res Commun 176 1991 690 697
17. J.D. Robertson, V. Gogvadze, B. Zhivotovsky, and S. Orrenius Distinct pathways for stimulation of cytochrome c release by etoposide J Biol Chem 275 2000 32438 32443
18. J.S. Carew, Y. Zhou, M. Albitar, J.D. Carew, M.J. Keating, and P. Huang Mitochondrial DNA mutations in primary leukemia cells after chemotherapy: clinical significance and therapeutic implications Leukemia 17 2003 1437 1447
19. S. Toyokuni, K. Okamoto, J. Yodoi, and H. Hiai Persistent oxidative stress in cancer FEBS Lett 358 1995 1 3
20. K.B. Wallace, and A.A. Starkov Mitochondrial targets of drug toxicity Annu Rev Pharmacol Toxicol 40 2000 353 388
21. J. O'Neil, M. Manion, P. Schwartz, and D.M. Howkenbery Promises and challenges of targeting Bcl-2 anti-apoptotic proteins for cancer therapy Biochim Biophys Acta 1705 2004 43 51
22. 1-ATPase/ATP synthase by polyphenolic phytochemicals Br J Pharmacol 130 2000 1115 1123
23. H. Miyoshi, M. Inoue, S. Okamoto, M. Ohshima, K. Sakamoto, and H. Iwamura Probing the ubiquinone reduction site of mitochondrial complex I using novel cationic inhibitors J Biol Chem 272 1997 16176 16183
24. 1-ATPase Chem Biol 8 2001 71 80
25. I. Royo, N. DePedro, E. Estornell, D. Cortes, F. Pelaez, and J.R. Tormo In vitro antitumor SAR of threo/cis/threo/cis/erythro bis-THF acetogenins: correlations with their inhibition of mitochondrial complex I Oncol Res 13 2003 521 528
26. N. Li, K. Ragheb, G. Lawler, J. Sturgis, B. Rajwa, and J.A. Melendez Mitochondrial complex I inhibitor rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production J Biol Chem 278 2003 8516 8525
27. J. Golab, D. Nowis, M. Skrzycki, H. Czeczot, A. Baranczyk-Kuzma, and G.M. Wilczynski Antitumor effects of photodynamic therapy are potentiated by 2-methoxyestradiol. A superoxide dismutase inhibitor J Biol Chem 278 2003 407 414
28. Y. Zhou, E.O. Hileman, W. Plunkett, M.J. Keating, and P. Huang Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents Blood 101 2003 4098 4104
29. A. Czyz, A. Szewczyk, M.J. Nalecz, and L. Wojtczak The role of mitochondrial potassium fluxes in controlling the protonmotive force in energized mitochondria Biochem Biophys Res Commun 210 1995 98 104
30. K.D. Garlid, P. Paucek, V. Yarov-Yarovoy, X. Sun, and P.A. Schindler The mitochondrial KATP channel as a receptor for potassium channel openers J Biol Chem 271 1996 8796 8799
31. Y.S. Lee, M.M. Sayeed, and R.D. Wurster In vitro antitumor activity of cromakalim in human brain tumor cells Pharmacology 49 1994 69 74
32. M. Abdul, A. Santo, and N. Hoosein Activity of potassium channel-blockers in breast cancer Anticancer Res 23 2003 3347 3351
33. K.D. Garlid, P. Paucek, V. Yarov-Yarovoy, H.N. Murray, R.B. Darbenzio, and A.J. D'Alonzo Cardioprotective effect of diazoxide and its interaction with mitochondrial ATP-sensitive K+ channels. Possible mechanism of cardioprotection Circ Res 81 1997 1072 1082
34. K.K. Tai, Z.A. McCrossan, and G.W. Abbott Activation of mitochondrial ATP-sensitive potassium channels increases cell viability against rotenone-induced cell death J Neurochem 84 2003 1193 1200
35. E. Holmuhamedov, L. Lewis, M. Bienengraeber, M. Holmuhamedova, A. Jahangir, and A. Terzic Suppression of human tumor cell proliferation through mitochondrial targeting FASEB J 16 2002 1010 1016
36. D.M. Kopustinskiene, P. Pollesello, and N.E. Saris Potassium-specific effects of levosimendan on heart mitochondria Biochem Pharmacol 68 2004 807 812
37. + channel openers NS1619 and NS004 as inhibitors of mitochondrial function in glioma cells Biochem Pharmacol 65 2003 1827 1834
38. J.S. Armstrong, B. Hornung, P. Lecane, D.P. Jones, and S.J. Knox Rotenone-induced G2/M cell cycle arrest and apoptosis in a human B lymphoma cell-line PW Biochem Biophys Res Commun 289 2001 973 978
39. A.S. Breathnach Azelaic acid: potential as a general antitumoural agent Med Hypotheses 52 1999 221 226
40. R. Cariati, P. Zancai, E. Righetti, S. Rizzo, A. De Rossi, and M. Boiocchi Inhibition of oxidative phosphorylation underlies the antiproliferative and proapoptotic effects of mofarotene (Ro 40-8757) in Burkitt's lymphoma cells Oncogene 22 2003 906 918
41. R.M. Kluck, E. Bossy-Wetzel, D.R. Green, and D.D. Newmeyer The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis Science 275 1997 1132 1136
42. A. Piche, J. Grim, C. Rancourt, J. Gomez-Navarro, J.C. Reed, and D.T. Curiel Modulation of Bcl-2 protein levels by an intracellular anti-Bcl-2 single-chain antibody increases drug-induced cytotoxicity in the breast cancer cell-line MCF-7 Cancer Res 58 1998 2134 2140
43. R.S. Herbst, and S.R. Frankel Oblimersen sodium (Genasense bcl-2 antisense oligonucleotide): a rational therapeutic to enhance apoptosis in therapy of lung cancer Clin Cancer Res 10 2004 s4245 s4248
44. S. Frantz Lessons learnt from Genasense's failure Nat Rev Drug Discov 3 2004 542 543
45. J.L. Wang, D. Liu, Z.J. Zhang, S. Shan, X. Han, and S.M. Srinivasula Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells Proc Natl Acad Sci USA 97 2000 7124 7129
46. S. Wang, D. Yang, M.E. Lippman, and Targeting Bcl-2 Bcl-XL with non-peptidic small-molecule antagonists Semin Oncol 30 2003 133 142
47. C.L. Oliver, M.B. Miranda, S. Shangary, S. Land, S. Wang, and D.E. Johnson (-)-Gossypol acts directly on the mitochondria to overcome Bcl-2 and Bcl-XL-mediated apoptosis resistance Mol Cancer Ther 4 2005 23 31
48. K. Koya, Y. Li, H. Wang, T. Ukai, N. Tatsuta, and M. Kawakami MKT-077 a novel rhodacyanine dye in clinical trials, exhibits anticarcinoma activity in preclinical studies based on selective mitochondrial accumulation Cancer Res 56 1996 538 543
49. C.D. Britten, E.K. Rowinsky, S.D. Baker, G.R. Weiss, L. Smith, and J. Stephenson A phase I and pharmacokinetic study of the mitochondrial-specific rhodacyanine dye analog MKT6077 Clin Cancer Res 6 2000 42 49
50. R. Wadhwa, T. Sugihara, A. Yoshida, H. Nomura, R.R. Reddel, and R. Simpson Selective toxicity of MKT-077 to cancer cells is mediated by its binding to the hsp70 family protein mot-2 and reactivation of p53 function Cancer Res 15/60 2000 6818 6821
51. G. Beutner, A. Ruck, B. Riede, and D. Brdiczka Complexes between porin, hexokinase, mitochondrial creatine kinase and adenylate translocator display properties of the permeability transition pore. Implication for regulation of permeability transition by the kinases Biochim Biophys Acta 1368 1998 7 18
52. N. Zamzami, P. Marchetti, M. Castedo, T. Hirsch, S.A. Susin, and B. Masse Inhibitors of permeability transition interfere with the disruption of the mitochondrial transmembrane potential during apoptosis FEBS Lett 384 1996 53 57
53. A.P. Halestrap, C.P. Connern, E.J. Griffiths, P.M. Kerr, and Cyclosporin A binding to mitochondrial cyclophilin inhibits the permeability transition pore and protects hearts from ischaemia/reperfusion injury Mol Cell Biochem 174 1997 167 172
54. X. Bian, F.M. Hughes Jr., Y. Huang, J.A. Cidlowski, and J.W. Putney Jr. Roles of cytoplasmic Ca2+ and intracellular Ca2+ stores in induction and suppression of apoptosis in S49 cells Am J Physiol 272 1997 C1241 C1249
55. P.J. Barnard, M.V. Baker, S.J. Berners-Price, and D.A. Day Mitochondrial permeability transition induced by dinuclear gold(I)-carbene complexes: potential new antimitochondrial antitumour agents J Inorg Biochem 98 2004 1642 1647
56. S. Kajimoto, N. Takanashi, T. Kajimoto, M. Xu, J. Cao, and Y. Masuda Sophoranone, extracted from a traditional Chinese medicine Shan Dou Gen, induces apoptosis in human leukemia U937 cells via formation of reactive oxygen species and opening of mitochondrial permeability transition pores Int J Cancer 99 2002 879 890
57. V.R. Fantin, M.J. Berardi, L. Scorrano, S. Korsmeyer, and P. Leder A novel mitochondriotoxic small molecule that selectively inhibits tumor cell growth Cancer Cell 2 2002 29 42
58. V.R. Fantin, and P. Leder F16, a mitochondriotoxic compound, triggers apoptosis or necrosis depending on the genetic background of the target carcinoma cell Cancer Res 64 2004 329 336
59. K. Miyako, T. Irie, T. Muta, S. Umeda, Y. Kai, and T. Fujiwara 1-Methyl-4-phenylpyridinium ion (MPP+) selectively inhibits the replication of mitochondrial DNA Eur J Biochem 259 1999 412 418
60. S. Fulda, C. Scaffidi, S.A. Susin, P.H. Krammer, G. Kroemer, and M.E. Peter Activation of mitochondria and release of mitochondrial apoptogenic factors by betulinic acid J Biol Chem 273 1998 33942 33948
61. L. Ravagnan, I. Marzo, P. Costantini, S.A. Susin, N. Zamzami, and P.X. Petit Lonidamine triggers apoptosis via a direct, Bcl-2-inhibited effect on the mitochondrial permeability transition pore Oncogene 18 1999 2537 2546
62. P. Marchetti, N. Zamzami, B. Joseph, S. Schraen-Maschke, C. Mereau-Richard, and P. Costantini The novel retinoid 6-[3-(1-adamantyl)-4- hydroxyphenyl]-2-naphtalene carboxylic acid can trigger apoptosis through a mitochondrial pathway independent of the nucleus Cancer Res 59 1999 6257 6266
63. A.S. Belzacq, C. El Hamel, H.L. Vieira, I. Cohen, D. Haouzi, and D. Metivier Adenine nucleotide translocator mediates the mitochondrial membrane permeabilization induced by lonidamine, arsenite and CD437 Oncogene 20 2001 7579 7587
64. Y. Zheng, Y. Shi, C. Tian, C. Jiang, H. Jin, and J. Chen Essential role of the voltage-dependent anion channel (VDAC) in mitochondrial permeability transition pore opening and cytochrome c release induced by arsenic trioxide Oncogene 23 2004 1239 1247
65. H. Pelicano, L. Feng, Y. Zhou, J.S. Carew, E.O. Hileman, and W. Plunkett Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism J Biol Chem 278 2003 37832 37839
66. 3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins Blood 88 1996 1052 1061
67. S. Di Cosimo, G. Ferretti, P. Papaldo, P. Carlini, A. Fabi, and F. Cognetti Lonidamine: efficacy and safety in clinical trials for the treatment of solid tumors Drugs Today 39 2003 157 174
68. F. Bono, I. Lamarche, V. Prabonnaud, G. Le Fur, and J.M. Herbert Peripheral benzodiazepine receptor agonists exhibit potent antiapoptotic activities Biochem Biophys Res Commun 265 1999 457 461
69. D. Decaudin, M. Castedo, F. Nemati, A. Beurdeley-Thomas, G. De Pinieux, and A. Caron Peripheral benzodiazepine receptor ligands reverse apoptosis resistance of cancer cells in vitro and in vivo Cancer Res 62 2002 1388 1393
70. R.B. Walter, B.W. Raden, M.R. Cronk, I.D. Bernstein, F.R. Appelbaum, and D.E. Banker The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicin Blood 103 2004 4276 4284
71. D. Decaudin Peripheral benzodiazepine receptor and its clinical targeting Anti-Cancer Drugs 15 2004 737 745
72. B.S. Iyengar, R.T. Dorr, and W.A. Remers Chemical basis for the biological activity of imexon and related cyanoaziridines J Med Chem 47 2004 218 223
73. K. Dvorakova, C.M. Payne, M.E. Tome, M.M. Briehl, M.A. Vasquez, and C.N. Waltmire Molecular and cellular characterization of imexon-resistant RPMI8226/I myeloma cells Mol Cancer Ther 1 2002 185 195
74. J.M. Grad, E. Cepero, and L.H. Boise Mitochondria as targets for established and novel anti-cancer agents Drug Resist Updat 4 2001 85 91
75. D.S. Cassarino, and J.P. Bennett Jr. An evaluation of the role of mitochondria in neurodegenerative diseases: mitochondrial mutations and oxidative pathology, protective nuclear responses and cell death in neurodegeneration Brain Res 1 1999 20 25